42 results about "Activating transcription factor" patented technology

The invention discloses a bacillus subtilis polygene editing and expression adjusting and controlling system based on CRISPR Cpf1. Through a constructed Cpf1 expression vector pHT-XCR6 and a constructed crRNA array expression vector pcrF11, complete knockout of 2 genes, basic group modification of 6 genes and knock-in of 1 gene can be completed at one time. The vector pHT-XCR6 contains NgAgo protein, and is used for promoting recA mediated homologous recombination. Besides, a vector pLCg6-dCpf1-remA (used for integral expression of a Cpf1 mutant dCpf1 inactivated by deoxyribonuclease and fusion protein of an activating transcription factor remA on a bacillus subtilis genome) and a vector pcra3 (used for integral expression of a crRNA array on the bacillus subtilis genome) are constructed,and can be used for performing transcription inhibition and activation on different genes. The invention further establishes an economic efficient crRNA array assembling method of which the name is SOMACA (Synthetic Oligos Mediated Assembly of crRNA Array), and through synthesizing short-single-strand DNA (60nt ), a needed crRNA array is inserted in the vector pcrF11 or pcra3 and is used for guiding Cpf1 or dCpf1-remA for gene editing and expression adjustment and control.

The invention discloses a novel cotton fiber secondary development specific expression gene GhNAC1 full-length sequence, and relates to an important cotton fiber development-associated regulator gene element. The GhNAC1 gene contains three exons and two introns, and is coded with an NAC (N Acetyl L Cysteine) transcription factor. A large quantity of mRNAs (messenger Ribonucleic Acids) of the gene are accumulated specifically at the secondary development stage of the cotton fiber cells, which indicates that the gene is a fiber secondary wall development specific gene. GhNAC1 protein is positioned in a cell nucleolus and has the capability of activating transcription independently, which indicates that the protein serving as a transcription activating factor plays a role in cotton fiber development. GhNAC1 is expressed excessively in arabidopsis, so that leaves crimp upwards, cell walls are thickened, ectopic sedimentation of lignin and the like is detected in foliar epidermic cells, so that the hemicellulose content of foliar cells is greatly increased. As proved by the results, the GhNAC1 can be used for regulating the biosynthesis of cell secondary walls, and plays a key role in the developing process of cotton fiber.

The invention discloses a plasmid carrier pair and immune cells modified by the same, and an application thereof in preparation of drugs for local secretion of IL12 or regulating expression of IL12 and preparation of drugs for enhancing the killing effect of CAR-T cells, and also discloses a composition and combined drug box of the immune cells and the CAR-T cells. The plasmid vector pair includesa first carrier and a second carrier, the first carrier contains a Notch core, and other coding nucleic acid molecules of extracellular and intracellular segments, wherein the intracellular segment preferably contains transcription activating factors; the second carrier contains nucleic acid molecules specifically recognizing and binding with the intracellular segment in the first carrier and nucleic acid molecules encoding IL12. The combined drug box comprises a drug box A containing the immune cells and a drug box B containing the CAR-T cells. The immune cells can control the expression andsecretion of IL12, and have the effect of synergistically treating tumors with the CAR-T cells.

Transgenic oleaginous yeast having increased oil content comprising increased Yap1 transcription factor activity, wherein the increased oil content is compared to the oil content of a non-transgenic oleaginous yeast, are described herein. The increased Yap1 transcription factor activity results from overexpressing a Yap1 transcription factor, by increasing the interaction between the transcription factor and a protein that is capable of activating the transcription factor, or by a combination thereof. Methods of using these yeast strains are also described.

hABCG2, a member of the ATP-Binding Cassette transporters has been identified as a protective pump against endogenous and exogenous toxic agents. ABCG2 was shown to be expressed at high levels in stem cells, and variably regulated during cell differentiation. It is demonstrated herein that functional ABCG2 is expressed in human monocyte-derived dendritic cells by the activation of a nuclear hormone receptor, PPARg. The present results uncovered a mechanism by which up-regulation of functional ABCG2 expression can be achieved via exogenous or endogenous activation of the lipid activated transcription factor, PPARg. Thus the invention relates to combined treatments by PPARg agonists and cytotoxic drugs transportable by ABCG2, various treatments in the field of neoplastic diseases as well as cell therapy, including autologous cell therapy, as well as kits and composition therefor. Method for protecting cells against cytotoxic drugs are also provided.

A method of increasing the insulin sensitivity of insulin resistant cells includes administering to the cells an amount of all-trans-retinoic acid effective to activate transcription factor perosixome proliferator-activated receptor (PPAR) β / δ of the cells.

The present invention relates to a method for obtaining an activation profile of a biological sample comprising disposing onto a solid support in a pre-determined spatial arrangement a subset of capture molecules able to interact with one or more activated transcription factor(s) present in the biology cell sample, contacting the biological sample upon the solid support under conditions allowing their interaction, monitoring signals resulting from their interaction, and providing a cellular activation profile from the detected signals.

The invention relates to the field of cell culture technology. It concerns the knockdown, using RNA interference, or gene knockout, of activating transcription factor 6 beta (ATF6B), or the combination of ceramide synthase 2 (CERS2) and TBC1 domain family member 20 (TBC1 D20) proteins, which play central roles in the cellular secretion pathway. This downregulation leads to improved secretion of biopharmaceutically relevant products produced in mammalian cells. The invention specifically relates to mammalian cells having enhanced secretion of a recombinant therapeutic protein compared to a control cell, a method of producing said mammalian cell, a method for the production of a recombinant secreted therapeutic protein and the use of said mammalian cell for increasing the yield of a recombinant secreted therapeutic protein.

The invention provides an application of dermal fibroblasts in the treatment of melanoma, which belongs to the technical field of biomedicine. Through research, the present invention finds that in vitro, dermal fibroblasts expressing a high level of activating transcription factor 3 can inhibit the proliferation and migration of melanoma cells, accompanied by the downregulation of different cytokines (including IL‑6). In vivo, dermal fibroblasts with high expression of activator transcription factor 3 reduced tumor formation. Addition of recombinant IL‑6 to melanoma cells reversed those in vitro and in vivo effects, suggesting that activating transcription factor 3 expression in dermal fibroblasts regulates melanoma progression through the IL‑6 / STAT3 pathway, with promising practical applications value.

Compounds as inhibitors of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treatment of viral infections, neurodegenerative diseases, vascular diseases, or cancer.

The invention provides a progesterone whole-cell biosensor as well as a preparation method and application thereof. The invention designs a design strategy of a non-natural transcription factor DLA based on a tiny conformation change of a ligand binding domain LBD after a target molecule is combined with a receptor of the target molecule. A simulation result shows that a pronucleus LexA, a truncated LBD from a progestational hormone receptor and a pronucleus B42 jointly form the DLA with a transcription factor function. In order to verify the effectiveness of the design, DLA is used as a transcription activating factor for controlling green fluorescent protein transcription, and a progesterone specific whole-cell biosensor is successfully constructed, and the sensitivity index (EC50) of the progesterone specific whole-cell biosensor is 27 [mu] g / L and reaches the clinical detection level. According to the present invention, the scientific, accurate and rapid progesterone content detection method is established, and the method is particularly suitable for direct detection of trace progesterone in the sample, and is the progesterone microbiological detection method with the progesterone microbiological detection method with the progesterone microbiological detection prospect.

The invention provides a sequencing method of rice bacterial leaf blight activating transcription factor like effector gene, can effectively separate repeating region of nearly each TAL effector family gene, performs accurate sequencing and assembly to the TAL effector family gene, and provides essential support for the functional research and application of TAL effectors.

The present invention relates to an anti-STAT3 bispecific antibody having a cell-penetrating ability, and a pharmaceutical composition containing same and, more specifically, to an anti-STAT3 bispecific antibody comprising a site specifically binding to STAT3 and a DNA binding site enabling cell-penetration, and a pharmaceutical composition containing same as an active ingredient. It has been ascertained that a STAT3 / DNA bispecific antibody according to the present invention comprises a DNA binding site, which allows penetration into cells and specifically binds to intranuclear DNA, so as to be capable of overcoming limitations of a conventional antibody drug, which only targets proteins existing outside the cells, and binds specifically only to STAT3 in the active phosphorylated form so as to be capable of inhibiting the transcription factor activity thereof, thereby being effectively usable in the development of: therapeutic agents, having no side effects, for associated diseases caused by the activation of STAT3, for example, therapeutic agents for various carcinomas associated with the activation of STAT3; drugs capable of inhibiting cancer metastasis induced by the activationof STAT3; and therapeutic agents, having no side effects, for inflammatory diseases caused by the activation of STAT3, including rheumatoid arthritis.